Reported Saturday, Novartis' Latest Phase III Data For Fabhalta (iptacopan) In C3 glomerulopathy (C3G) A Significant 35.1% Reduction In Proteinuria Compared To Placebo

Author: Benzinga Newsdesk | May 28, 2024 03:51am

• Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2,3
   
• Fabhalta showed a favorable safety profile with no new safety signals1
   
• C3G, an ultra-rare kidney disease caused by alternative complement pathway overactivation, progresses to kidney failure in ∼50% of patients within 10 years4-7; currently there are no treatments approved for C3G7-9
   
• Fabhalta, an oral Factor B inhibitor of the alternative complement pathway, selectively targets the underlying cause of C3G1; late-stage development program ongoing across several other rare diseases10-13

Posted In: NVS